Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-03-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of providing guarantees for a controlling subsidiary by the company. It details the guarantee amount, the internal decision process, the necessity and reasonableness of the guarantee, and the board's opinion. It includes financial figures related to the guarantee but does not contain comprehensive financial statements or detailed financial performance data. The document is a formal disclosure about a specific financing-related activity (providing guarantees) rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the guarantee. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees provided to subsidiaries.
2026-03-13 Chinese
安杰思关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the use of part of its idle funds for cash management. It details the investment purpose, amount, types of products, investment period, source of funds, implementation method, approval process, risk control measures, and impact on daily operations. The document is a formal announcement of a financing or capital management activity, specifically about the company's plan to invest idle funds in financial products. It does not contain financial statements or quarterly/yearly results, nor is it a report or transcript. It is not a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment activities.
2026-03-11 Chinese
安杰思2025年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a '2025年度业绩快报公告' which translates to '2025 Annual Performance Express Report Announcement'. It contains preliminary financial data for the year 2025, including revenue, profit, net assets, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a note that the final audited data will be disclosed in the 2025 Annual Report. The document is relatively short (2556 characters) and serves as an initial announcement of the company's yearly financial results, not a full detailed annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER). FY 2025
2026-02-26 Chinese
安杰思关于签署募集资金专户存储四方及五方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of regulatory agreements related to the management and supervision of funds raised from a recent public stock issuance by Hangzhou Anjiesi Medical Technology Co., Ltd. It details the agreements signed with banks and the sponsor institution to manage the raised funds, including the establishment of special accounts and supervisory protocols. The document references the approval of the initial public offering, the amount raised, and the use of funds, but it does not contain financial statements, audit opinions, or detailed financial performance data. It is a formal announcement about the regulatory and compliance arrangements for the raised funds, not a financial report or earnings release. The document length is substantial but it is focused on regulatory agreements and fund management protocols. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2026-02-26 Chinese
安杰思2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at an extraordinary shareholders meeting (临时股东会决议公告) held on January 26, 2026. It includes information about the meeting attendance, voting results on specific proposals, and legal compliance statements. The content focuses on the voting outcomes and procedural details of the shareholders meeting rather than presenting a full report or financial statements. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1912 characters) and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2026-01-26 Chinese
安杰思2026年第一次临时股东会法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the convening, attendance, and voting procedures of the 2026 first extraordinary shareholders' meeting of Hangzhou Anjiesi Medical Technology Co., Ltd. It details the meeting notice, attendance, voting procedures, and results, and concludes on the legality and validity of the meeting and its resolutions. The document is not a report of financial results, audit, or management discussion, but a legal opinion on a shareholders meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides official voting results and legal validation of the shareholders meeting resolutions. The document length is 3431 characters, which is consistent with a detailed legal opinion rather than a brief announcement or a full annual/interim report. Therefore, the best classification is DVA with high confidence.
2026-01-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.